



A review on - Obesity can be treated using Advanced Microneedle Therapy

Aakanksha Babu Babar

UG Student, LNBCIOP Raigaon, Satara.

Abstract:

Obesity a big problem observed in now days. Which has been identified as a chronic disease .So to treat obesity degradable microneedles are composed in the form of patches.

For create an obese model, the fat community was fed a calorie-dense foods for 3 to 4 months Following that, the obese subjects were separated as 4 group : control , unloaded M N, CL-31624 3 M N, and vaccine . CL316243 (1 mg/(kgday)) was injected subcutaneously into the injection group of mice for 15 days. In addition, for fifteen days, CL-31624 3 M N group gives in a low quantity (0.1 mg/(kgday)). mass o f an CL-31624 3 M N along with inoculation groups decreased . When compared to the injectable dose, CL-316243 is administered to hypodermic body fat better improve and evenly via MN arrays. This method offers a novel and practical approach to treating obesity.

Keywords: Obesity, Microneedle arry, Adipose tissue

Introduction:

Obesity affects 13% of adults worldwide. 39 percent of adults in the globe are overweight. Globally, one in every five children and adolescents is overweight.

Obesity management and treatment is becoming increasingly popular. WA T is primarily found in the groyne area. The basic role of the mesenteric region which is stock as stout.

The majority of BA T spread in scapula , the nape , and different parts of the body Its primary purpose is to transform the Energy derived from food calories. Transitioning from a WA T has evolved into a BA T-like composition .a popular way on fight fatty. Were considerably superior to hardly any medications now accept as supplementary through th e US (F D A).

Currently, the better medicine, discovered found as WA T, is CL31624 3 tissue. CL316243. It has been found in research to stimulate the breakdown of gut whit e lean in mice. UCPI is activated in obese mice, causing the BAT stands for browning of white fat However, while those medications was administered t o forbearing using typical directing way, adverse Result as, diarrhoea and even heart disease also reported .Although standard hypodermic needles can be used, Due to poor patient compliance, there may be discomfort and infection at the injection site. Besides, Because obese is no instantly dangerous, it is critical t o begin therapy as soon as possible. acceptable, secure, and practical novel of transdermic remedy transport has emerged i n recent years. MN transdermal delivery typically involves 10 - 100 of MN s . and a 1–2 cm² transdermal patch. It adheres to the epidermis and penetrates the skin.Their is two benefits conventional transdermal administration and injections First and foremost, it is quick, simple, and painless. It's also non-harmful.

2 . Matter and technique

A .pdm s M N master mold devising

The dimethicone dimethylpolysiloxane mould made b y pouring a PDMS polymer precursor onto a top-of-the-line copp er mast er with an elastomer Ten tomb are arranged i n an array. Following degasifying i n vacuity to thirty minutes and thermic sorting toward 65°C for two hours, respectively, Remove the metal substrate with care by slowly peeling it away.a duplicated PDMS master mould was obtained.

B . Formulation o f MNs that are compound and recyclable.

MN made b y pouring two different mixture into mould in a specific order. PL A contributed to boost the automotive force while PLG A will offer main command the dru g delivery. The casting solution produced by dissolving 0.45 g of calcium carbonate in water.In 2 mL dioxane , dissolve PLG A along with 0.0 5 g PL A, then add a 75 g CL-316243 solution, then finally combining it more 1,4-Dioxacyclohexane along make the Last discharging mixture , use deionized water.

C. Dimension of automotive force MN 's mechanical strength determined utilising an electronic universal testing machine and force- relegation analysis. China). MN was immobilised on the nethermost sword plate and customised into a 10 10 array. The distance between te M N tips and th e to p

detector was originally placed to 0.65 mm. The top detector moved toward the MN at 0.1 mm/min. The force and reformation of the inquiry as it was pressed on the MN were recorded on a computer until the MN was destroyed.

D. Cutaneous absorption test on mice

Following the NIH mouse's nape was killed, a cordless trimmer was used to shave the mouse's fur on the back. Depilatory cream was used to remove the hair, which was then wiped clean with saline. The skin swells up once the hair is thrown out. The stratum corneum was sliced off and placed with the stratum corneum facing down on a clean face.

The subcutaneous fat subcutaneous and connective tissue were gutted using a cotton ball.

Water-soak the material with physiological saline.

Normal saline was used to wash the skin several times.

Following desiccation, the set mouse's skin penetration was pushed for 30 seconds with the thumb to observe the perforation MNs on the skin have a unique geomorphologic. To make effects simple, we utilized a 0.4 percent diamine blue result to completely dye the pin-hole array. After 1 millisecond, the colour that remained on the skin face was rinsed down, and the skin was evaluated as well as being mugged.

Conclusion :

MNs made with our materials and procedures have a high mechanical strength and a soft skin fit that can be readily pressed with the thumb. CL-316243 was able to avoid the unfavourable effects of oral delivery as well as the large dose (1 mg/(kgday)) necessary for injection in MNs, achieving 0.1 mg/(kgday) (kgday). Clinical trials can be done at a later date. Overall, we believe that this polymer MN loading medicine has a lot of promise.

Reference :

- Xie, Y.; Shao, R.; Lin, Y.; Wang, C.; Tan, Y.; Xie, W.; Sun, S. Improved Therapeutic Efficiency against Obesity through Transdermal Drug Delivery Using Microneedle Arrays. *Pharmaceutics* 2021, 13, 827. <https://doi.org/10.3390/pharmaceutics13060827>
- Xiao, C.; Goldgof, M.; Gavrilova, O.; Reitman, M.L. Anti-obesity and metabolic efficacy of the beta3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22 degrees C. *Obesity (Silver Spring)* 2015, 23, 1450–1459. [CrossRef]
- Shin, W.; Okamoto-Ogura, Y.; Machida, K.; Tsubota, A.; Nio-Kobayashi, J.; Kimura, K. Impaired adrenergic agonist-dependent beige adipocyte induction in aged mice. *Obesity (Silver Spring)* 2017, 25, 417–423. [CrossRef]
- Qiu, Y.; Sun, Y.; Xu, D.; Yang, Y.; Liu, X.; Wei, Y.; Chen, Y.; Feng, Z.; Li, S.; Reyad-Ul Ferdous, M.; et al. Screening of FDA-approved drugs identifies sunitinib as a modulator of UCP1 expression in brown adipose tissue. *EBioMedicine* 2018, 37, 344–355. [CrossRef] [PubMed]
- Dunham-Snary, K.J.; Sandel, M.W.; Westbrook, D.G.; Ballinger, S.W. A method for assessing mitochondrial bioenergetics in whole white adipose tissues. *Redox Biol.* 2014, 2, 656–660. [CrossRef]
- Kajimura, S.; Spiegelman, B.M.; Seale, P. Brown and Beige Fat: Physiological Roles beyond Heat Generation. *Cell Metab.* 2015, 22, 546–559. [CrossRef]
- Tews, D.; Pula, T.; Funcke, J.B.; Jastroch, M.; Keuper, M.; Debatin, K.M.; Wabitsch, M.; Fischer-Posovszky, P. Elevated UCP1 levels are sufficient to improve glucose uptake in human white adipocytes. *Redox Biol.* 2019, 26, 101286. [CrossRef]
- Vitali, A.; Murano, I.; Zingaretti, M.C.; Frontini, A.; Ricquier, D.; Cinti, S. The adipose organ of obesity-prone C57BL/6J mice is composed of mixed white and brown adipocytes. *J. Lipid Res.* 2012, 53, 619–629. [CrossRef] [PubMed]
- Cypess, A.M.; Weiner, L.S.; Roberts-Toler, C.; Franquet-Elia, E.; Kessler, S.H.; Kahn, P.A.; English, J.; Chatman, K.; Trauger, S.A.; Doria, A.; et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. *Cell Metab.* 2015, 21, 33–38. [CrossRef]
- He, P.; Hou, B.; Li, Y.; Xu, C.; Ma, P.; Lam, S.M.; Gil, V.; Yang, X.; Yang, X.; Zhang, L.; et al. Lipid Profiling Reveals Browning Heterogeneity of White Adipose Tissue by Beta3-Adrenergic Stimulation. *Biomolecules* 2019, 9, 444. [CrossRef] [PubMed]
- Xue, B.; Rim, J.S.; Hogan, J.C.; Coulter, A.A.; Koza, R.A.; Kozak, L.P. Genetic variability affects the development of brown adipocytes in white fat but not in interscapular brown fat. *J. Lipid Res.* 2007, 48, 41–51. [CrossRef] [PubMed]
- Larrañeta, E.; McCrudden, M.T.C.; Courtenay, A.J.; Donnelly, R.F. Microneedles: A New Frontier in Nanomedicine Delivery. *Pharm. Res.* 2016, 33, 1055–1073. [CrossRef]
- Prausnitz, M.R. Microneedles for transdermal drug delivery. *Adv. Drug Deliv. Rev.* 2004, 56, 581–587. [CrossRef] [PubMed]
- Cheung, K.; Das, D.B. Microneedles for drug delivery: Trends and progress. *Drug Deliv.* 2016, 23, 2338–2354. [CrossRef]